GlassScriptPhysician profile
Daniel G Bruetman
NPI 1972583417
$2,553.52
in general payments reported to CMS, 2019-2025
31 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $65.94 · 2021: $171 · 2022: $542 · 2023: $124 · 2024: $464 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.74 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $394.23 | 2019-2025 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $276.73 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $242.62 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $132.65 | 2022-2025 | Opdivo |
| Genentech USA, INC. | $132.05 | 2019-2024 | Itovebi |
| Janssen Biotech, INC. | $127.48 | 2021-2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2019 | |
| Pfizer INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $98.33 | 2020-2024 | Imfinzi |
| Abbvie INC. | $76.87 | 2019-2025 | |
| Incyte Corporation | $74.27 | 2021-2023 | Jakafi |
| Ipsen Biopharmaceuticals, INC | $69.99 | 2024 | |
| Seagen INC. | $66.89 | 2021-2022 | |
| Amgen INC. | $65.62 | 2019-2023 | Lumakras, Xgeva, Vectibix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $63.72 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.81 | 2022-2024 | Alunbrig |
| Daiichi Sankyo INC. | $43.82 | 2024-2025 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $40.47 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $39.72 | 2025 | |
| Springworks Therapeutics, INC. | $31.40 | 2025 | Ogsiveo |
| Astellas Pharma US INC | $23.51 | 2024 | Padcev |
| Verastem, INC. | $21.46 | 2019 | |
| Lilly USA, LLC | $21.03 | 2021 | |
| Celgene Corporation | $21.01 | 2022 | |
| Cardinal Health 414 LLC | $20.38 | 2023 | |
| Accord Healthcare, INC. | $17.09 | 2024 | |
| Stemline Therapeutics INC. | $16.89 | 2025 | Orserdu |
| Emd Serono, INC. | $11.48 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bruetman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.